RETINITIS PIGMENTOSA (RP) is an inherited, degenerative eye disease that causes severe vision impairment due to the progressive degeneration of the rod photoreceptor cells in the retina . This form of retinal dystrophy manifests initial symptoms independent of age; thus, RP diagnosis occurs anywhere from early infancy to late adulthood. Patients in the early stages of RP first notice compromised peripheral and dim light vision due to the decline of the rod photoreceptors. The progressive rod degeneration is later followed by abnormalities in the adjacent retinal pigment epithelium (RPE) and the deterioration of cone photoreceptor cells. As peripheral vision becomes increasingly compromised, patients experience progressive "tunnel vision" and eventual blindness. Affected individuals may additionally experience defective light-dark adaptations, nyctalopia (night blindness), and the accumulation of bone spicules in the fundus .
* 1 Signs and symptoms
* 2 Causes
* 2.1 Genetics
* 3 Pathophysiology * 4 Diagnosis * 5 Treatment * 6 Prognosis * 7 Epidemiology * 8 Research * 9 Notable cases * 10 See also * 11 References * 12 External links
SIGNS AND SYMPTOMS
The initial retinal degenerative symptoms of Retinitis Pigmentosa are characterized by decreased night vision (nyctalopia ) and the loss of the mid-peripheral visual field. The rod photoreceptor cells, which are responsible for low-light vision and are orientated in the retinal periphery, are the retinal processes affected first during non-syndromic forms of this disease. Visual decline progresses relatively quickly to the far peripheral field, eventually extending into the central visual field as tunnel vision increases. Visual acuity and color vision can become compromised due to accompanying abnormalities in the cone photoreceptor cells, which are responsible for color vision, visual acuity, and sight in the central visual field. The progression of disease symptoms occurs in a symmetrical manner, with both the left and right eyes experiencing symptoms at a similar rate.
A variety of indirect symptoms characterize Retinitis Pigmentosa along with the direct effects of the initial rod photoreceptor degeneration and later cone photoreceptor decline. Phenomena such as photophobia , which describes the event in which light is perceived as an intense glare, and photopsia , the presence of blinking or shimmering lights within the visual field, often manifest during the later stages of RP. Findings related to RP have often been characterized in the fundus of the eye as the OPHTHALAMIC TRIAD. This includes the development of (1) a mottled appearance of the retinal pigment epithelium (RPE) caused by bone spicule formation, (2) a waxy appearance of the optic nerve, and (3) the attentuation of blood vessels in the retina.
Non-syndromic RP usually presents a variety of the following symptoms:
* Night blindness or nyctalopia ; * Tunnel vision (due to loss of peripheral vision); * Latticework vision; * Photopsia (blinking/shimmering lights); * Photophobia (Aversion to glare); * Development of bone spicules in the fundus; * Slow adjustment from dark to light environments and vice versa; * Blurring of vision; * Poor color separation; * Loss of central vision; * Eventual blindness
RP may be: (1) Non-syndromic, that is, it occurs alone, without any other clinical findings, (2) Syndromic, with other neurosensory disorders, developmental abnormalities, or complex clinical findings, or (3) Secondary to other systemic diseases.
* RP combined with deafness (congenital or progressive) is called Usher syndrome . * Alport's syndrome is associated with RP and an abnormal glomerular-basement membrane leading nephrotic syndrome and inherited as X-linked dominant. * RP combined with ophthalmoplegia , dysphagia , ataxia , and cardiac conduction defects is seen in the mitochondrial DNA disorder Kearns-Sayre syndrome (also known as Ragged Red Fiber Myopathy ) * RP combined with retardation, peripheral neuropathy , acanthotic (spiked) RBCs, ataxia, steatorrhea , is absence of VLDL is seen in abetalipoproteinemia . * RP is seen clinically in association with several other rare genetic disorders (including muscular dystrophy and chronic granulomatous disease) as part of McLeod syndrome . This is an X-linked recessive phenotype characterized by a complete absence of XK cell surface proteins, and therefore markedly reduced expression of all Kell red blood cell antigens. For transfusion purposes these patients are considered completely incompatible with all normal and K0/K0 donors. * RP associated with hypogonadism, and developmental delay with an autosomal recessive inheritance pattern is seen with Bardet-Biedl syndrome
Other conditions include neurosyphilis , toxoplasmosis and Refsum\'s disease .
Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degeneration .
There are multiple genes that, when mutated, can cause the retinitis pigmentosa phenotype . Inheritance patterns of RP have been identified as autosomal dominant, autosomal recessive, X-linked, and maternally (mitochondrially ) acquired, and are dependent on the specific RP gene mutations present in the parental generation. In 1989, a mutation of the gene for rhodopsin , a pigment that plays an essential part in the visual transduction cascade enabling vision in low-light conditions, was identified. The rhodopsin gene encodes a principal protein of photoreceptor outer segments. Mutations in this gene most commonly presents as missense mutations or misfolding of the rhodopsin protein, and most frequently follow autosomal dominant inheritance patterns. Since the discovery of the rhodopsin gene, more than 100 RHO mutations have been identified, accounting for 15% of all types of retinal degeneration , and approximately 25% of autosomal dominant forms of RP.
Up to 150 mutations have been reported to date in the opsin gene associated with the RP since the Pro23His mutation in the intradiscal domain of the protein was first reported in 1990. These mutations are found throughout the opsin gene and are distributed along the three domains of the protein (the intradiscal, transmembrane , and cytoplasmic domains ). One of the main biochemical causes of RP in the case of rhodopsin mutations is protein misfolding , and the disruption of molecular chaperones . It was found that the mutation of codon 23 in the rhodopsin gene, in which proline is changed to histidine , accounts for the largest fraction of rhodopsin mutations in the United States . Several other studies have reported various codon mutations associated with Retinitis Pigmentosa, including Thr58Arg, Pro347Leu, Pro347Ser, as well as deletion of Ile-255. In 2000, a rare mutation in codon 23 was reported causing autosomal dominant retinitis pigmentosa, in which proline changed to alanine . However, this study showed that the retinal dystrophy associated with this mutation was characteristically mild in presentation and course. Furthermore, there was greater preservation in electroretinography amplitudes than the more prevalent Pro23His mutation.
Mutations in four pre-mRNA splicing factors are known to cause autosomal dominant retinitis pigmentosa. These are PRPF3 (human PRPF3 is HPRPF3; also PRP3), PRPF8 , PRPF31 and PAP1 . These factors are ubiquitously expressed and it is proposed that defects in a ubiquitous factor (a protein expressed everywhere) should only cause disease in the retina because the retinal photoreceptor cells have a far greater requirement for protein processing (rhodopsin ) than any other cell type.
The somatic, or X-linked inheritance patterns of RP are currently identified with the mutations of six genes, the most common occurring at specific loci in the RPGR and RP2 genes.
OMIM GENE TYPE
312600 RP2 Retinitis pigmentosa-2
600852 CA4 Retinitis pigmentosa-17
602772 EYS Retinitis pigmentosa-25
608380 CERKL Retinitis pigmentosa-26
613428 C2orf71 Retinitis pigmentosa 54
613617 ZNF513 Retinitis pigmentosa 58
613341 LRAT Retinitis pigmentosa, juvenile
268000 CRX Retinitis pigmentosa, late-onset dominant
Scanning electron micrograph depicting the retinal rod and cone photoreceptors. The elongated rods are colored yellow and orange, while the shorter cones are colored red.
A variety of retinal molecular pathway defects have been matched to multiple known RP gene mutations. Mutations in the rhodopsin gene, which is responsible for the majority of autosomal-dominantly inherited RP cases, disrupts the rod-opsin protein essential for translating light into decipherable electrical signals within the phototransduction cascade of the central nervous system. Defects in the activity of this G-protein-coupled receptor are classified into distinct classes that depend on the specific folding abnormality and the resulting molecular pathway defects. The Class I mutant protein's activity is compromised as specific point mutations in the protein-coding amino acid sequence affect the pigment protein's transportation into the outer segment of the eye, where the phototransduction cascade is localized. Additionally, the misfolding of Class II rhodopsin gene mutations disrupts the protein's conjunction with 11-cis-retinal to induce proper chromophore formation. Additional mutants in this pigment-encoding gene affect protein stability, disrupt mRNA integrity post-translationally, and affect the activation rates of transducin and opsin optical proteins.
Additionally, animal models suggest that the retinal pigment epithelium fails to phagocytose the outer rod segment discs that have been shed, leading to an accumulation of outer rod segment debris. In mice that are homozygous recessive for retinal degeneration mutation, rod photoreceptors stop developing and undergo degeneration before cellular maturation completes. A defect in cGMP-phosphodiesterase has also been documented; this leads to toxic levels of cGMP.
An accurate diagnosis of retinitis pigmentosa relies on the documentation of the progressive loss photoreceptor cell function, confirmed by a combination of visual field and visual acuity tests, fundus and optical coherence imagery, and electroretinography (ERG),
Visual field and acuity tests measure and compare the size of the patient's field of vision and the clarity of their visual perception with the standard visual measurements associated with healthy 20/20 vision. Clinical diagnostic features indicative of Retinitis Pigmentosa include a substantially small and progressively decreasing visual area in the visual field test, and compromised levels of clarity measured during the visual acuity test. Additionally, optical tomography such as fundus and retinal (optical coherence) imagery provide further diagnostic tools when determining an RP diagnosis. Photographing the back of the dilated eye allows the confirmation of bone spicule accumulation in the fundus, which presents during the later stages of RP retinal degeneration. Combined with cross-sectional imagery of optical coherence tomography, which provides clues into photoreceptor thickness, retinal layer morphology, and retinal pigment epithelium physiology, fundus imagery can help determine the state of RP progression.
While visual field and acuity test results combined with retinal imagery support the diagnosis of Retinitis Pigmentosa, additional testing is necessary to confirm other pathological features of this disease. Electroretinography (ERG) confirms the RP diagnosis by evaluating functional aspects associated with photoreceptor degeneration, and can detect physiological abnormalities before the initial manifestation of symptoms. An electrode lens is applied to the eye as photoreceptor response to varying degrees of quick light pulses is measured. Patients exhibiting the Retinitis Pigmentosa phenotype would show decreased or delayed electrical response in the rod photoreceptors, as well as possibly compromised cone photoreceptor cell response.
The patient's family history is also considered when determining a diagnosis due to the genetic mode of inheritance of Retinitis Pigmentosa. At least 35 different genes or loci are known to cause "nonsyndromic RP" (RP that is not the result of another disease or part of a wider syndrome ). Indications of the RP mutation type can be determine through DNA testing , which is available on a clinical basis for:
* RLBP1 (autosomal recessive, Bothnia type RP)
For all other genes (e.g. DHDDS ), molecular genetic testing is available on a research basis only.
RP can be inherited in an autosomal dominant , autosomal recessive , or X-linked manner. X-linked RP can be either recessive , affecting primarily only males, or dominant , affecting both males and females, although males are usually more mildly affected. Some digenic (controlled by two genes) and mitochondrial forms have also been described.
Genetic counseling depends on an accurate diagnosis, determination of the mode of inheritance in each family, and results of molecular genetic testing.
There is no cure for retinitis pigmentosa; however, the efficacy and safety of various prospective treatments are currently being evaluated. The efficiency of various supplements, such as Vitamin A, DHA, and Lutein, in delaying disease progression remains an unresolved, yet prospective treatment option. Clinical trials investigating optic prosthetic devices, gene therapy mechanisms, and retinal sheet transplantations are active areas of study in the partial restoration of vision in retinitis pigmentosa patients.
Studies have demonstrated the delay of rod photoreceptor degeneration by the daily intake of 15000 IU (equivalent to 4.5 mg) of vitamin A palmitate ; thus, stalling disease progression in some patients. Recent investigations have shown that proper vitamin A supplementation can postpone blindness by up to 10 years (by reducing the 10% loss pa to 8.3% pa) in some patients in certain stages of the disease.
The Argus retinal prosthesis became the first approved treatment for the disease in February 2011, and is currently available in Germany, France, Italy, and UK. Interim results on 30 patients long term trials were published in 2012. The Argus II retinal implant has also received market approval in the USA. The device may help adults with RP who have lost the ability to perceive shapes and movement to be more mobile and to perform day-to-day activities. In June 2013, twelve hospitals in the USA announced to soon accept consultation for patients with RP in preparation for the launch of Argus II later that year. The Alpha-IMS is a subretinal implant involving the surgical implantation of a small image-recording chip beneath the optic fovea . Measures of visual improvements from Alpha-IMS studies require the demonstration of the device's safety before proceeding with clinical trials and granting market approval.
The goal of gene therapy studies is to virally supplement retinal cells expressing mutant genes associated with the Retinitis Pigmentosa phenotype with healthy forms of the gene; thus, allowing the repair and proper functioning of retinal photoreceptor cells in response to the instructions associated with the inserted healthy gene. Clinical trials investigating the insertion of the healthy RPE65 gene in retinas expressing the LCA2 Retinitis Pigmentosa phenotype measured modest improvements in vision; however, the degradation of retinal photoreceptors continued at the disease-related rate. Likely, gene therapy may preserve remaining healthy retinal cells while failing to repair the earlier accumulation of damage in already diseased photoreceptor cells. Response to gene therapy would theoretically benefit young patients exhibiting the shortest progression of photoreceptor decline; thus, correlating to a higher possibility of cell rescue via the healthy inserted gene.
The progressive nature of and lack of a definitive cure for Retinitis Pigmentosa contribute to the inevitably discouraging outlook for patients with this disease. While complete blindness is rare, the patient's visual acuity and visual field will continue to decline as initial rod photoreceptor and later cone photoreceptor degradation proceeds. Possible treatments remain in the research and clinical trial stages; however, treatment studies concerning visual restoration in Retinitis Pigmentosa prove promising for the future.
Studies indicate that children carrying the disease genotype benefit from presymptomatic counseling in order to prepare for the physical and social implications associated with progressive vision loss. While the psychological prognosis can be slightly alleviated with active counseling the physical implications and progression of the disease depend largely on the age of initial symptom manifestation and the rate of photoreceptor degradation, rather than access to prospective treatments. Corrective visual aids and personalized vision therapy provided by Low Vision Specialists may help patients correct slight disturbances in visual acuity and optimize their remaining visual field. Support groups, vision insurance, and lifestyle therapy are additional useful tools for those managing progressive visual decline.
Retinitis Pigmentosa is the leading cause of inherited blindness, with approximately 1/4,000 individuals experiencing the non-syndromic form of their disease within their lifetime. It is estimated that 1.5 million people worldwide are currently affected. Early onset RP occurs within the first few years of life and is typically associated with syndromic disease forms, while late onset RP emerges from early to mid adulthood.
Due to the genetic inheritance patterns of RP, many isolate populations exhibit higher disease frequencies or increased prevalence of a specific RP mutation. Pre-existing or emerging mutations that contribute to rod photoreceptor degeneration in Retinitis Pigmentosa are passed down through familial lines; thus, allowing certain RP cases to be concentrated to specific geographical regions with an ancestral history of the disease. Several hereditary studies have been performed to determine the varying prevalence rates in Maine (USA), Birmingham (England), Switzerland (affects 1/7000), Denmark (affects 1/2500), and Norway. Navajo Indians display an elevated rate of RP inheritance as well, which is estimated as affecting 1 in 1878 individuals. Despite the increased frequency of RP within specific familial lines, the disease is considered non-discriminatory and tends to equally affect all world populations.
Future treatments may involve retinal transplants , artificial retinal implants , gene therapy , stem cells , nutritional supplements , and/or drug therapies .
2006: Stem cells: UK Researchers working with mice, transplanted mouse stem cells which were at an advanced stage of development, and already programmed to develop into photoreceptor cells , into mice that had been genetically induced to mimic the human conditions of retinitis pigmentosa and age-related macular degeneration . These photoreceptors developed and made the necessary neural connections to the animal's retinal nerve cells, a key step in the restoration of sight. Previously it was believed that the mature retina has no regenerative ability. This research may in the future lead to using transplants in humans to relieve blindness.
2010: A possible gene therapy seems to work in mice.
2012: Scientists at the
Columbia University Medical Center
2012: Scientists at the University of Miami Bascom Palmer Eye Institute presented data showing protection of photoreceptors in an animal model when eyes were injected with mesencephalic astrocyte-derived neurotrophic factor (MANF ).
Researchers at the University of California, Berkeley were able to restore vision to blind mice by exploiting a "photoswitch" that activates retinal ganglion cells in animals with damaged rod and cone cells.
2016: RetroSense Therapeutics aims to inject viruses with DNA from light-sensitive algae into the eyes of several blind people (which have Retinitis_pigmentosa). If successful, they will be able to see in black and white.
* Neil Fachie , British paralympic cyclist * Lindy Hou , Australian tandem cyclist and triathlete * Jon Wellner , American actor * Steve Wynn , American business magnate and Las Vegas casino developer * Steve Lonegan , Mayor of Bogota, New Jersey, Republican candidate for U.S. Senate
* Cone dystrophy * Visual prosthetic * List of eye diseases and disorders * Retinal regeneration * Progressive retinal atrophy for the condition in dogs * Retinal degeneration (rhodopsin mutation) * Adeno associated virus and gene therapy of the human retina * Retinitis Pigmentosa International * Tauroursodeoxycholic acid (TUDCA)
* ^ A B Busskamp, V.; Duebel, J.; Balya, D.; Fradot, M.; Viney, T.
J.; Siegert, S.; Groner, A. C.; Cabuy, E.; Forster, V.; Seeliger, M.;
Biel, M.; Humphries, P.; Paques, M.; Mohand-Said, S.; Trono, D.;
Deisseroth, K.; Sahel, J. A.; Picaud, S.; Roska, B. (2010). "Genetic
Reactivation of Cone Photoreceptors Restores Visual Responses in
Retinitis Pigmentosa". Science. 329 (5990): 413–7. Bibcode
:2010Sci...329..413B. PMID 20576849 . doi :10.1126/science.1190897 .
* ^ Koenekoop, Robert K; Loyer, Magali; Hand, Collette K; Al Mahdi,
Huda; Dembinska, Olga; Beneish, Raquel; Racine, Julie; Rouleau, Guy A
RPGR mutations with distinct retinitis pigmentosa
phenotypes in French-Canadian families". American Journal of
Ophthalmology. 136 (4): 678–87. PMID 14516808 . doi
* ^ Understanding
* ^ Farrar, G.J.; Kenna, P. F.; Humphries, P (2002). "NEW EMBO
MEMBer\'s REVIEW: On the genetics of retinitis pigmentosa and on
mutation-independent approaches to therapeutic intervention" . The
EMBO Journal. 21 (5): 857–64. PMC 125887 . PMID 11867514 . doi
* ^ A B Shintani, Kelly; Shechtman, Diana L.; Gurwood, Andrew S.
(2009). "Review and update: Current treatment trends for patients with
retinitis pigmentosa". Optometry. 80 (7): 384–401. PMID 19545852 .
doi :10.1016/j.optm.2008.01.026 .
* ^ A B Soucy, E; Wang, Y; Nirenberg, S; Nathans, J; Meister, M
(1998). "A Novel Signaling Pathway from Rod Photoreceptors to Ganglion
Cells in Mammalian Retina". Neuron. 21 (3): 481–93. PMID 9768836 .
doi :10.1016/S0896-6273(00)80560-7 .
* ^ A B C Hartong, Dyonne T; Berson, Eliot L; Dryja, Thaddeus P
Retinitis pigmentosa". The Lancet. 368 (9549): 1795–1809.
PMID 17113430 . doi :10.1016/S0140-6736(06)69740-7 .
* ^ Daiger, S P; Sullivan, L S; Bowne, S J (2013). "